Krisvert 16mg Tablet contains Betahistine dihydrochloride 16mg as the active ingredient, indicated primarily for the management of vertigo and balance disorders associated with Ménière’s disease. Betahistine acts as a histamine analogue, exerting its therapeutic effect by improving microcirculation in the inner ear and reducing vestibular system sensitivity. This leads to a decrease in the frequency and severity of vertigo attacks, tinnitus, and hearing loss. Krisvert is typically prescribed to alleviate symptoms such as dizziness, nausea, and imbalance, thereby enhancing patients’ quality of life. The medication is administered orally, with dosage and duration tailored according to clinical response and patient tolerance. Betahistine is generally well tolerated; however, mild adverse effects such as gastrointestinal discomfort, headache, or allergic reactions may occur. It is contraindicated in patients with pheochromocytoma and should be used cautiously in individuals with asthma or peptic ulcer disease. Regular monitoring and adherence to prescribed dosing are essential to optimize therapeutic outcomes. Patients are advised to consult healthcare professionals before initiating or discontinuing therapy with Krisvert 16mg Tablet to ensure safe and effective use.